Axsome Therapeutics (AXSM) Misses Q4 EPS by 58c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Axsome Therapeutics (AXSM) PT Raised to $200 at Truist Securities
February 18, 2025 1:13 PM ESTTruist Securities analyst Joon Lee raised the price target on Axsome Therapeutics (NASDAQ: AXSM) to $200.00 (from $190.00) while maintaining a Buy rating.
The analyst comments "4Q24. No surprises to results preannounced in January. More importantly, Ph3 study of solriamfetol in... More
